Compare SUPN & NMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUPN | NMM |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | Greece |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 1.3B |
| IPO Year | 2012 | 2007 |
| Metric | SUPN | NMM |
|---|---|---|
| Price | $49.07 | $53.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $61.60 | N/A |
| AVG Volume (30 Days) | ★ 599.9K | 95.9K |
| Earning Date | 02-24-2026 | 02-12-2026 |
| Dividend Yield | N/A | ★ 0.39% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 8.91 |
| Revenue | $681,539,000.00 | ★ $1,311,114,000.00 |
| Revenue This Year | $8.32 | N/A |
| Revenue Next Year | $23.36 | $15.22 |
| P/E Ratio | ★ N/A | $5.74 |
| Revenue Growth | ★ 4.54 | N/A |
| 52 Week Low | $29.16 | $28.37 |
| 52 Week High | $57.65 | $56.44 |
| Indicator | SUPN | NMM |
|---|---|---|
| Relative Strength Index (RSI) | 51.23 | 57.34 |
| Support Level | $51.01 | $50.93 |
| Resistance Level | $52.30 | $52.65 |
| Average True Range (ATR) | 1.45 | 1.13 |
| MACD | -0.12 | 0.03 |
| Stochastic Oscillator | 37.06 | 79.52 |
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.